학술논문
The Safety Profiles of Orlistat and Sibutramine: Results of Prescription-Event Monitoring Studies in England.
Document Type
Article
Source
Obesity (19307381); Nov2007, Vol. 15 Issue 11, p2712-2722, 11p, 4 Charts
Subject
Language
ISSN
19307381
Abstract
This article discusses findings of a study which examined the safety profiles of the anti-obesity agents orlistat and sibutramine using prescription-event monitoring. Licensed in Great Britain in December 1998 and May 2001 for the treatment of obesity, orlistat is a gastrointestinal lipase inhibitor while sibutramine is a serotonin-noradrenaline reuptake inhibitor. Several side effects of orlistat include diarrhea, flatus and oily or fatty stools.